UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): June 24, 2004



                           Integrated BioPharma, Inc.
                           --------------------------
             (Exact name of registrant as specified in its charter)


           Delaware                     000-28876               22-2407475
           --------                     ---------               ----------
(State or other jurisdiction of   (Commission File Number)    (IRS Employer
 incorporation or organization)                              Identification No.)


            225 Long Avenue
          Hillside, New Jersey                             07205
          --------------------                             ------
(Address of principal executive offices)                 (Zip Code)


       Registrant's telephone number, including area code: (973) 926-0816



                                 Not Applicable
          (Former name or former address, if changed since last report)







Item 5.      Other Events and Regulation FD Disclosure.

         On June 24, 2004, Integrated BioPharma, Inc., a Delaware corporation
(the "Company"), issued a press release announcing that the Company had approved
a stock repurchase program authorizing the Company to repurchase shares of the
Company's common stock worth up to $3 million, and that the Company was not
aware of any reason for the recent unusual trading activity affecting its common
stock. The press release is attached as an exhibit to this Report.


Item 7.      Financial Statements and Exhibits

(c) Exhibits.

Exhibit No.  Description
-----------  -----------
   99.1      Press Release issued by Integrated BioPharma, Inc. on June 24, 2004





                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


Date:  June 25, 2004                INTEGRATED BIOPHARMA, INC.


                                    By: /s/ Eric Friedman
                                    ---------------------
                                    Eric Friedman
                                    Vice President and Chief Financial Officer






Exhibit Index


Exhibit No.  Description
-----------  -----------
   99.1      Press Release issued by Integrated BioPharma, Inc. on June 24, 2004